Hudson Bay Capital Management LP Purchases 321,631 Shares of Vir Biotechnology, Inc. (NASDAQ:VIR)

Hudson Bay Capital Management LP lifted its stake in Vir Biotechnology, Inc. (NASDAQ:VIR - Free Report) by 60.9% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 849,873 shares of the company's stock after purchasing an additional 321,631 shares during the period. Hudson Bay Capital Management LP owned 0.62% of Vir Biotechnology worth $6,238,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently modified their holdings of VIR. SBI Securities Co. Ltd. bought a new position in shares of Vir Biotechnology in the 4th quarter worth about $60,000. PNC Financial Services Group Inc. increased its stake in shares of Vir Biotechnology by 31.8% in the 4th quarter. PNC Financial Services Group Inc. now owns 8,288 shares of the company's stock worth $61,000 after acquiring an additional 1,999 shares in the last quarter. KBC Group NV increased its stake in shares of Vir Biotechnology by 136.5% in the 4th quarter. KBC Group NV now owns 8,970 shares of the company's stock worth $66,000 after acquiring an additional 5,177 shares in the last quarter. CIBC Asset Management Inc bought a new position in shares of Vir Biotechnology in the 4th quarter worth about $74,000. Finally, Syon Capital LLC bought a new position in shares of Vir Biotechnology in the 4th quarter worth about $77,000. 65.32% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Vir Biotechnology

In other news, Director George A. Scangos sold 10,964 shares of the business's stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $9.81, for a total value of $107,556.84. Following the transaction, the director now owns 708,295 shares of the company's stock, valued at approximately $6,948,373.95. The trade was a 1.52% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Backer Marianne De sold 79,712 shares of the company's stock in a transaction on Thursday, April 3rd. The shares were sold at an average price of $5.95, for a total transaction of $474,286.40. Following the sale, the chief executive officer now directly owns 769,505 shares in the company, valued at approximately $4,578,554.75. The trade was a 9.39% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 98,049 shares of company stock valued at $649,232 over the last 90 days. 15.60% of the stock is currently owned by corporate insiders.

Vir Biotechnology Stock Up 1.1%

NASDAQ:VIR traded up $0.05 during trading hours on Thursday, hitting $4.55. 1,231,070 shares of the stock traded hands, compared to its average volume of 1,366,913. Vir Biotechnology, Inc. has a 1 year low of $4.33 and a 1 year high of $14.45. The company has a market cap of $628.98 million, a price-to-earnings ratio of -1.16 and a beta of 1.36. The stock has a 50 day moving average price of $6.02 and a 200 day moving average price of $7.85.

Vir Biotechnology (NASDAQ:VIR - Get Free Report) last issued its quarterly earnings results on Wednesday, May 7th. The company reported ($0.88) earnings per share for the quarter, missing the consensus estimate of ($0.83) by ($0.05). Vir Biotechnology had a negative net margin of 678.40% and a negative return on equity of 36.71%. The firm had revenue of $3.03 million for the quarter, compared to analysts' expectations of $8.59 million. During the same period in the prior year, the firm earned ($0.48) EPS. Vir Biotechnology's revenue for the quarter was down 94.6% compared to the same quarter last year. Equities analysts forecast that Vir Biotechnology, Inc. will post -3.92 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research analysts have recently issued reports on VIR shares. The Goldman Sachs Group dropped their target price on shares of Vir Biotechnology from $28.00 to $21.00 and set a "buy" rating on the stock in a research note on Thursday, April 17th. HC Wainwright reissued a "buy" rating and issued a $110.00 target price on shares of Vir Biotechnology in a report on Friday, February 28th. Needham & Company LLC lowered their price target on Vir Biotechnology from $19.00 to $14.00 and set a "buy" rating on the stock in a report on Monday. Finally, Barclays lifted their price objective on Vir Biotechnology from $26.00 to $31.00 and gave the stock an "overweight" rating in a report on Friday, February 28th. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $32.86.

Vir Biotechnology Company Profile

Vir Biotechnology, Inc, an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV).